630-22-8 Usage
Description
2,2-Dimethylthiopropionamide is an organic compound that serves as a key intermediate in the synthesis of various pharmaceuticals and chemical compounds.
Uses
Used in Pharmaceutical Industry:
2,2-Dimethylthiopropionamide is used as a reagent for the synthesis of Dabrafenib, a BRAF kinase inhibitor that is utilized in the treatment of BRAF V600-mutation positive carcinomas. This gene mediates cell growth and is often activated by cancerous mutations.
Used in Chemical Synthesis:
2,2-Dimethylthiopropionamide is also employed as a reagent in the preparation of sulfonyl-substituted 4,5-diarylthiazoles. These compounds function as cyclooxygenase-2 inhibitors, which are anti-inflammatory agents.
Check Digit Verification of cas no
The CAS Registry Mumber 630-22-8 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 6,3 and 0 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 630-22:
(5*6)+(4*3)+(3*0)+(2*2)+(1*2)=48
48 % 10 = 8
So 630-22-8 is a valid CAS Registry Number.
InChI:InChI=1/C5H11NS/c1-5(2,3)4(6)7/h1-3H3,(H2,6,7)
630-22-8Relevant articles and documents
Substituted thiazoles for the treatment of inflammation
-
, (2008/06/13)
A class of substituted thiazolyl compounds is described for use in treating inflammation disorders. Compounds are defined by Formula II STR1 wherein R1 is selected from hydrido, alkyl, haloalkyl, cyanoalkyl, alkylamino, aralkyl, arylamino, heteroarylsulfonylalkyl, heteroarylsulfonylhaloalkyl, aralkylamino, aryloxyalkyl, alkoxycarbonyl, aryl optionally substituted at a substitutable position with one or more radicals selected from halo and alkoxy, and heterocyclic optionally substituted at a substitutable position with one or more radicals selected from halo and alkyl; wherein R4 is selected from alkyl and amino; and wherein R5 is selected from aryl and heteroaryl; wherein R5 is optionally substituted at a substitutable position with one or more radicals selected from halo, alkyl and alkoxy; provided R5 is not phenyl at position 4 when R1 is α,α-bis(trifluoromethyl)methanol and R4 is methyl; or a pharmaceutically-acceptable salt thereof.